Re:Irregularities found during FDA inspection of Intas Pharm...
by bamfly on Wednesday June 28, 2023 @11:13AM
(#36507656)
Yeah, our experience is something like:
in terms of perceived effect. They're sure as hell not close enough to be considered equivalent under any reasonable classification scheme (but I assume insurers really, really, really want the generic to count as equivalent and work to ensure it is so-regarded—and, anyway, availability's so spotty that we just have to take what we can get regardless).
[ Parent
| on HN ]